Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.31 |
| ▸ | FEN1 | P39748 | 4/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12740314 | 1.00 | NAAA (0.32) | NAAAPTPN11FFAR4ALOX5APFEN1 | |
| SCHEMBL12740312 | 1.00 | NAAA (0.32) | NAAAPTPN11FFAR4ALOX5APFEN1 | |
| SCHEMBL12736741 | 1.00 | NAAA (0.32) | NAAAPTPN11FFAR4ALOX5APFEN1 | |
| SCHEMBL12736745 | 1.00 | NAAA (0.32) | NAAAPTPN11FFAR4ALOX5APFEN1 | |
| SCHEMBL12736746 | 1.00 | NAAA (0.32) | NAAAPTPN11FFAR4ALOX5APFEN1 | |
| SCHEMBL12740311 | 0.99 | NAAA (0.32) | NAAAPTPN11FFAR4ALOX5APFEN1 | |
| SCHEMBL12736740 | 0.99 | NAAA (0.32) | NAAAPTPN11FFAR4ALOX5APFEN1 | |
| SCHEMBL12740310 | 0.96 | FFAR4 (0.34) | NAAAFFAR4ALOX5APFEN1FPR2 | |
| SCHEMBL12736737 | 0.96 | FFAR4 (0.34) | NAAAFFAR4ALOX5APFEN1FPR2 | |
| SCHEMBL12733889 | 0.91 | ALOX5AP (0.35) | PTPN11ALOX5APFEN1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | NAAA 3997/4885PTPN11 3889/4885FFAR4 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.